biotech
biotech Articles
Selecta Biosciences has filed its paperwork with the Securities and Exchange Commission to conduct an initial public offering (IPO) ahead. The company applied to list its common stock on The Nasdaq...
Published:
Last Updated:
Biotech is the one arena that still offers massive upside for investors — if they can pick the right companies that is. They could one day cure cancer, heart issues, diabetes and just about every...
Published:
Last Updated:
The analysts that were expecting earnings disappointments for this season appear to have been correct as many companies have fallen flat in the past few weeks.
Published:
Last Updated:
ASCO has just released the abstracts for its exhibitors ahead of the conference. For investors and analysts, sometimes winners or losers from the meeting can be divined ahead of time by these...
Published:
Last Updated:
Aduro BioTech has announced that the Phase 2b ECLIPSE trial did not meet the primary endpoint of an improvement in overall survival for patients with pancreatic cancer who had failed at least two...
Published:
Last Updated:
The king of biotech and pharma events is about to take place. The 2016 annual meeting of the American Society of Clinical Oncology (ASCO) is set to run from June 3 to June 7 in Chicago.
Published:
Last Updated:
AnaptysBio has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
The short interest data are out for the April 29 settlement date, and short interest moves were mixed in these selected biotech stocks.
Published:
Last Updated:
A Merrill Lynch report has a whole wave of companies featured as Global Ageing Primer Picks, including these biotech and pharmaceutical picks.
Published:
Last Updated:
Merus plans to offer more than 4 million shares within an expected price range of $14 to $16 per share in an initial public offering valued up to more than $79 million.
Published:
Last Updated:
Theravance Biopharma has announced that the FDA approved its supplemental New Drug Application for Vibativ (telavancin) to expand the product's label.
Published:
Last Updated:
A research report from Janney's Roy Buchanan issued on Friday included a fair value estimate for Geron shares that was more than 100% above the share price of the time.
Published:
Last Updated:
Several big FDA decisions should be coming up in the June quarter for the likes of AstraZeneca and Sarepta Therapeutics.
Published:
Last Updated:
Oncobiologics expects to price 5 million shares within the range of $11 to $13 per share in an initial public offering valued up to mroe than $74 million.
Published:
Last Updated:
Gilead Sciences saw a sell-off after the company posted less than favorable earnings, but one analyst thinks that investors have spoken too soon.
Published:
Last Updated: